Ampio Pharmaceuticals Inc

Find Ratings Reports
AMPE : AMEX : Health Care
$0.96 up 0.01 | 0.87%
Today's Range: 0.95 - 0.97
Avg. Daily Volume: 909,100
07/27/16 - 4:02 PM ET

Financial Analysis


AMPIO PHARMACEUTICALS INC's gross profit margin for the first quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Sales have remained unchanged, but net income increased. AMPIO PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 3.36 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has significantly decreased by 70.26% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY16 Q1 FY15
Net Sales ($mil)0.00.0
EBITDA ($mil)-6.12-5.59
EBIT ($mil)-6.42-5.79
Net Income ($mil)-6.77-7.28


Balance Sheet Q1 FY16 Q1 FY15
Cash & Equiv. ($mil)11.1143.27
Total Assets ($mil)21.8562.62
Total Debt ($mil)0.00.0
Equity ($mil)17.9260.28


Profitability Q1 FY16 Q1 FY15
Gross Profit Margin0.00.0
EBITDA Margin0.00.0
Operating Margin0.00.0
Sales Turnover0.050.0
Return on Assets-144.09-56.15
Return on Equity-175.71-55.28
Debt Q1 FY16 Q1 FY15
Current Ratio3.5319.88
Debt/Capital0.00.0
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q1 FY16 Q1 FY15
Shares outstanding (mil)52.0251.99
Div / share0.00.0
EPS-0.13-0.11
Book value / share0.341.16
Institutional Own % n/a n/a
Avg Daily Volume858339.0181526.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 2.87 indicates valuation on par with the S&P 500 average of 2.81 and a significant discount versus the industry average of 8.86. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. The valuation analysis reveals that, AMPIO PHARMACEUTICALS INC seems to be trading at a premium to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
AMPE NM Peers 45.39   AMPE NM Peers 31.23

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

AMPE's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

AMPE's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
AMPE NA Peers 16.56   AMPE NA Peers 0.58

Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.

Ratio not available.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
AMPE 2.87 Peers 8.86   AMPE 7.70 Peers -19.27

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

AMPE is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

AMPE is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
AMPE 45.17 Peers 23.05   AMPE 1684.37 Peers 6.33

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

AMPE is trading at a significant premium to its industry.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

AMPE has a sales growth rate that significantly exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades